**Global Demand for COVID-19 Vaccines and Competition:** The declining global demand for COVID-19 vaccines poses a significant challenge to Moderna's revenue stream, further exacerbated by strong competition from larger pharmaceutical companies like Pfizer.

**Regulatory Environment and Clinical Trial Success:** The company's future growth heavily relies on successful clinical trial outcomes and regulatory approvals for its expanding pipeline of mRNA therapies and vaccines. Significant regulatory hurdles, such as requests for additional efficacy data, and the inherent risks of preclinical and clinical development, are critical factors.

**Biotech Sector Sentiment and Broader Economic Factors:** General investor sentiment towards the biotechnology industry, coupled with broader macroeconomic conditions like inflation, interest rates, and the overall business cycle, can influence Moderna's stock valuation.